Latest Posts

mASCARA team setting up a local anogenital service. Anogenital HSIL is best managed in a multidisciplinary setting involving the sexual health, dermatology, obstetrics and gynaecology and colorectal teams. We are in the process of building a service targeting the early … Continued

An excellent read for the Christmas break. Here is a summary of the Review published by the mASCARA team: Anal cancer rates are on the rise, especially for women. Women with a background of genital dysplasia or cancer have been … Continued

mASCARA team at ESCP in Dublin, presenting our local data on the management of anal HSIL in women. Our audit highlighted that out of 91 women with anal cancer (between 2001 and 2022) only 1 was being monitored for anal … Continued

The mASCARA team attended ACPGBI in Edinburgh. Miss Sarah Mills presented at the Anal Cancer Symposium. There is an ongoing need to improve research focused around the early detection and prevention of anal cancer. The importance of an International Anal … Continued

Sarah and Danni both attended the IANS meeting in New York in June 2022. As well as enjoying the New York city life, we presented the study teams work on the treatment of early ASCC.

The results from the ANCHOR study have been published. This is the first randomised control trial to finally determine the benefit of treating anal HSIL in the prevention of anal squamous cell carcinoma in PLWH. The study showed a 57% … Continued

Danni and Sarah from the mASCARA team are attending the IANS Scientific Meeting  in Amsterdam in November. The programme looks excellent, in particular we are looking forward to the updates on the SPANC and ANCHOR trials.  We are also looking forward to … Continued

Members of the mASCARA team are attending the European Society of Coloproctology Conference later this month in Vienna where we will be presenting our work on Anal Intraepithelial Neoplasia topical and ablative treatments.   We are looking to make further collaborations … Continued